ArticlePloS one2025
Host responses to S. pneumoniae in wild type and Mertk mutant mice.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Streptococcus pneumoniae is the leading cause of community-acquired pneumonia. Mertk is a receptor tyrosine kinase and a member of the TAM family. It serves as an efferocytosis receptor involved in the recognition and removal of apoptotic debris by phagocytic cells, dampening the inflammatory response. Here we show that at 24h post-inoculation with S. pneumoniae, Mertk-/- mice generated through homologous recombination and backcrossed (HRB-Mertk-/- mice) have fewer bacteria present in their pneumonic lung than wild type mice. This enhanced clearance was not observed in Mertk-/- mice generated by CRISPR technology. The enhanced clearance of HRB-Mertk-/- mice was associated with fewer neutrophils and more IFNγ in the bronchoalveolar lavage, but was not prevented by a neutralizing IFNγ antibody. Mertk is highly expressed on alveolar macrophages. Transcriptomic changes observed in HRB-Mertk-/- alveolar macrophages were associated with leukocyte activation, cellular motility, and response to stimulus, suggesting that they are primed for an inflammatory response. HRB-Mertk-/- mice similarly had enhanced host defense pathways in S. pneumoniae-stimulated alveolar macrophages in vitro and in pneumonic lung tissue. However, HRB-Mertk-/- alveolar macrophages demonstrated no defect in phagocytosis and acidification in vivo, and genes and gene sets describing phagocytic pathways were not enriched, suggesting that the enhanced clearance may be through alterations in the lung microenvironment. HRB-Mertk-/- mice are reported to have a long 129P2 DNA insert (~645 genes) in chromosome 2 adjacent to Mertk, as well as other alterations at multiple sites. Thus, while Mertk deficiency may contribute to the enhanced bacterial clearance, it is not solely responsible, because the phenotype is not seen in the CRISPR-Mertk-/- mice. The 129P2 DNA insert in the HRB-Mertk-/- mice must be mediating at least some of this phenotype. Understanding the mechanistic differences and the means by which this 129P2 DNA insert enhances bacterial clearance remains critically important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.